Chromosomes, hypoxia, angiogenesis, and trial design: a brief history of renal cancer drug development.
Stadler
Walter
W
Department of Medicine, Sections of Hematology/Oncology and Urology, University of Chicago, Chicago, IL 60637, USA. wstadler@medicine.bsd.uchicago.edu
D000970:Antineoplastic Agents / Q000627:therapeutic use; D015687:Cell Hypoxia; D002877:Chromosomes, Human; D002986:Clinical Trials as Topic / Q000379:methods; D015195:Drug Design; D004341:Drug Evaluation / Q000379:methods; D006801:Humans; D007680:Kidney Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000235:genetics; D008954:Models, Biological; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000209:etiology; D012107:Research Design; D051794:Von Hippel-Lindau Tumor Suppressor Protein / Q000235:genetics / Q000502:physiology
D000970:Antineoplastic Agents; D051794:Von Hippel-Lindau Tumor Suppressor Protein; C497446:VHL protein, human